Skip to main content
Erschienen in: Skeletal Radiology 3/2023

26.07.2022 | Scientific Article

Diffusion-weighted imaging (DWI) in diagnosis, staging, and treatment response assessment of multiple myeloma: a systematic review and meta-analysis

verfasst von: Pooya Torkian, Bahar Mansoori, Jens Hillengass, Javid Azadbakht, Sina Rashedi, Sarah S. Lee, Behrang Amini, Pietro Andrea Bonaffini, Majid Chalian

Erschienen in: Skeletal Radiology | Ausgabe 3/2023

Einloggen, um Zugang zu erhalten

Abstract

Objective

To evaluate the role of diffusion-weighted imaging (DWI) in the initial diagnosis, staging, and assessment of treatment response in patients with multiple myeloma (MM).

Materials and methods

A systematic literature review was conducted in PubMed, the Cochrane Library, EMBASE, Scopus, and Web of Science databases. The primary endpoints were defined as the diagnostic performance of DWI for disease detection, staging of MM, and assessing response to treatment in these patients.

Results

Of 5881 initially reviewed publications, 33 were included in the final qualitative and quantitative meta-analysis. The diagnostic performance of DWI in the detection of patients with MM revealed pooled sensitivity and specificity of 86% (95% CI: 84–89) and 63% (95% CI: 56–70), respectively, with a diagnostic odds ratio (OR) of 14.98 (95% CI: 4.24–52.91). The pooled risk difference of 0.19 (95% CI: − 0.04–0.42) was reported in favor of upstaging with DWI compared to conventional MRI (value = 0.1). Treatment response evaluation and ADCmean value changes across different studies showed sensitivity and specificity of approximately 78% (95% CI: 72–83) and 73% (95% CI: 61–83), respectively, with a diagnostic OR of 7.21 in distinguishing responders from non-responders.

Conclusions

DWI is not only a promising tool for the diagnosis of MM, but it is also useful in the initial staging and re-staging of the disease and treatment response assessment. This can aid clinicians with earlier initiation or change in treatment strategy, which could have prognostic significance for patients.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Kyle RA, Durie BGM, Rajkumar SV, Landgren O, Blade J, Merlini G, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia. 2010;24:1121–7.CrossRef Kyle RA, Durie BGM, Rajkumar SV, Landgren O, Blade J, Merlini G, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia. 2010;24:1121–7.CrossRef
3.
Zurück zum Zitat Smith A, Wisloff F, Samson D. UK Myeloma Forum, Nordic Myeloma Study Group, British Committee for Standards in Haematology. Guidelines on the diagnosis and management of multiple myeloma 2005. Br J Haematol. 2006;132:410–51.CrossRef Smith A, Wisloff F, Samson D. UK Myeloma Forum, Nordic Myeloma Study Group, British Committee for Standards in Haematology. Guidelines on the diagnosis and management of multiple myeloma 2005. Br J Haematol. 2006;132:410–51.CrossRef
4.
Zurück zum Zitat Engelhardt M, Kleber M, Frydrychowicz A, Pache G, Schmitt-Gräff A, Wäsch R, et al. Superiority of magnetic resonance imaging over conventional radiographs in multiple myeloma. Anticancer Res. 2009;29:4745–50. Engelhardt M, Kleber M, Frydrychowicz A, Pache G, Schmitt-Gräff A, Wäsch R, et al. Superiority of magnetic resonance imaging over conventional radiographs in multiple myeloma. Anticancer Res. 2009;29:4745–50.
5.
Zurück zum Zitat Petralia G, Padhani AR, Pricolo P, Zugni F, Martinetti M, Summers PE, et al. Whole-body magnetic resonance imaging (WB-MRI) in oncology: recommendations and key uses. Radiol Med. 2019;124:218–33.CrossRef Petralia G, Padhani AR, Pricolo P, Zugni F, Martinetti M, Summers PE, et al. Whole-body magnetic resonance imaging (WB-MRI) in oncology: recommendations and key uses. Radiol Med. 2019;124:218–33.CrossRef
6.
Zurück zum Zitat Jacobs MA, Pan L, Macura KJ. Whole-body diffusion-weighted and proton imaging: a review of this emerging technology for monitoring metastatic cancer. Semin Roentgenol. 2009;44:111–22.CrossRef Jacobs MA, Pan L, Macura KJ. Whole-body diffusion-weighted and proton imaging: a review of this emerging technology for monitoring metastatic cancer. Semin Roentgenol. 2009;44:111–22.CrossRef
7.
Zurück zum Zitat Ghanem N, Lohrmann C, Engelhardt M, Pache G, Uhl M, Saueressig U, et al. Whole-body MRI in the detection of bone marrow infiltration in patients with plasma cell neoplasms in comparison to the radiological skeletal survey. Eur Radiol. 2006;16:1005–14.CrossRef Ghanem N, Lohrmann C, Engelhardt M, Pache G, Uhl M, Saueressig U, et al. Whole-body MRI in the detection of bone marrow infiltration in patients with plasma cell neoplasms in comparison to the radiological skeletal survey. Eur Radiol. 2006;16:1005–14.CrossRef
8.
Zurück zum Zitat Horger M, Weisel K, Horger W, Mroue A, Fenchel M, Lichy M. Whole-body diffusion-weighted MRI with apparent diffusion coefficient mapping for early response monitoring in multiple myeloma: preliminary results. AJR Am J Roentgenol. 2011;196:W790-795.CrossRef Horger M, Weisel K, Horger W, Mroue A, Fenchel M, Lichy M. Whole-body diffusion-weighted MRI with apparent diffusion coefficient mapping for early response monitoring in multiple myeloma: preliminary results. AJR Am J Roentgenol. 2011;196:W790-795.CrossRef
9.
Zurück zum Zitat Latifoltojar A, Hall-Craggs M, Bainbridge A, Rabin N, Popat R, Rismani A, et al. Whole-body MRI quantitative biomarkers are associated significantly with treatment response in patients with newly diagnosed symptomatic multiple myeloma following bortezomib induction. Eur Radiol. 2017;27:5325–36.CrossRef Latifoltojar A, Hall-Craggs M, Bainbridge A, Rabin N, Popat R, Rismani A, et al. Whole-body MRI quantitative biomarkers are associated significantly with treatment response in patients with newly diagnosed symptomatic multiple myeloma following bortezomib induction. Eur Radiol. 2017;27:5325–36.CrossRef
10.
Zurück zum Zitat Latifoltojar A, Yong KL, Hall-Craggs M, Rabin N, Popat R, Bainbridge A, et al. Whole body (WB) MRI in newly diagnosed multiple myeloma (MM): fat fraction changes at 8 weeks predict response to induction with bortezomib regimens. Blood. 2015;126:1850–1850.CrossRef Latifoltojar A, Yong KL, Hall-Craggs M, Rabin N, Popat R, Bainbridge A, et al. Whole body (WB) MRI in newly diagnosed multiple myeloma (MM): fat fraction changes at 8 weeks predict response to induction with bortezomib regimens. Blood. 2015;126:1850–1850.CrossRef
11.
Zurück zum Zitat Giles SL, Messiou C, Collins DJ, Morgan VA, Simpkin CJ, West S, et al. Whole-body diffusion-weighted MR imaging for assessment of treatment response in myeloma. Radiology. 2014;271:785–94.CrossRef Giles SL, Messiou C, Collins DJ, Morgan VA, Simpkin CJ, West S, et al. Whole-body diffusion-weighted MR imaging for assessment of treatment response in myeloma. Radiology. 2014;271:785–94.CrossRef
12.
Zurück zum Zitat Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic re MA, Palumbo A, et al., International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538–48.CrossRef Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic re MA, Palumbo A, et al., International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538–48.CrossRef
13.
Zurück zum Zitat International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121:749–57.CrossRef International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121:749–57.CrossRef
14.
Zurück zum Zitat Sachpekidis C, Mosebach J, Freitag MT, Wilhelm T, Mai EK, Goldschmidt H, et al. Application of 18F-FDG PET and diffusion weighted imaging (DWI) in multiple myeloma: comparison of functional imaging modalities. Am J Nucl Med Mol Imaging. 2015;5:479–92. Sachpekidis C, Mosebach J, Freitag MT, Wilhelm T, Mai EK, Goldschmidt H, et al. Application of 18F-FDG PET and diffusion weighted imaging (DWI) in multiple myeloma: comparison of functional imaging modalities. Am J Nucl Med Mol Imaging. 2015;5:479–92.
15.
Zurück zum Zitat Singh S, Pilavachi E, Dudek A, Bray TJP, Latifoltojar A, Rajesparan K, et al. Whole body MRI in multiple myeloma: optimising image acquisition and read times. PLoS ONE. 2020;15: e0228424.CrossRef Singh S, Pilavachi E, Dudek A, Bray TJP, Latifoltojar A, Rajesparan K, et al. Whole body MRI in multiple myeloma: optimising image acquisition and read times. PLoS ONE. 2020;15: e0228424.CrossRef
16.
Zurück zum Zitat Withofs N, Cousin F, Tancredi T, Simoni P, Prijck BD, Hafraoui K, et al. Comparison of combined whole-body [18F]NaF and [18F]FDG PET/CT versus MRI for the detection of myeloma lesions. The Journal of Nuclear Medicine. 2016;57:606–606. Withofs N, Cousin F, Tancredi T, Simoni P, Prijck BD, Hafraoui K, et al. Comparison of combined whole-body [18F]NaF and [18F]FDG PET/CT versus MRI for the detection of myeloma lesions. The Journal of Nuclear Medicine. 2016;57:606–606.
17.
Zurück zum Zitat Durie BGM, Harousseau J-L, Miguel JS, Bladé J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467–73.CrossRef Durie BGM, Harousseau J-L, Miguel JS, Bladé J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467–73.CrossRef
18.
Zurück zum Zitat Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328–46.CrossRef Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328–46.CrossRef
19.
Zurück zum Zitat Terpos E, Koutoulidis V, Fontara S, Zagouri F, Matsaridis D, Christoulas D, et al. Diffusion-weighted magnetic resonance imaging (DW-MRI) is able to distinguish diffuse from normal MRI pattern of marrow involvement in patients with multiple myeloma. Blood. 2014;124:3461–3461.CrossRef Terpos E, Koutoulidis V, Fontara S, Zagouri F, Matsaridis D, Christoulas D, et al. Diffusion-weighted magnetic resonance imaging (DW-MRI) is able to distinguish diffuse from normal MRI pattern of marrow involvement in patients with multiple myeloma. Blood. 2014;124:3461–3461.CrossRef
20.
Zurück zum Zitat Koutoulidis V, Fontara S, Terpos E, Zagouri F, Matsaridis D, Christoulas D, et al. Quantitative diffusion-weighted imaging of the bone marrow: an adjunct tool for the diagnosis of a diffuse MR imaging pattern in patients with multiple myeloma. Radiology. 2017;282:484–93.CrossRef Koutoulidis V, Fontara S, Terpos E, Zagouri F, Matsaridis D, Christoulas D, et al. Quantitative diffusion-weighted imaging of the bone marrow: an adjunct tool for the diagnosis of a diffuse MR imaging pattern in patients with multiple myeloma. Radiology. 2017;282:484–93.CrossRef
21.
Zurück zum Zitat Narquin S, Ingrand P, Azais I, Delwail V, Vialle R, Boucebci S, et al. Comparison of whole-body diffusion MRI and conventional radiological assessment in the staging of myeloma. Diagn Interv Imaging. 2013;94:629–36.CrossRef Narquin S, Ingrand P, Azais I, Delwail V, Vialle R, Boucebci S, et al. Comparison of whole-body diffusion MRI and conventional radiological assessment in the staging of myeloma. Diagn Interv Imaging. 2013;94:629–36.CrossRef
22.
Zurück zum Zitat Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467–73.CrossRef Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467–73.CrossRef
23.
Zurück zum Zitat Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36:842–54.CrossRef Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36:842–54.CrossRef
24.
Zurück zum Zitat Wang PF, Li YC, Xu YX, Wang XM, Guo LF, Fu C. [Role of whole-body diffusion weighted imaging (WB-DWI) in the diagnosis and monitoring of newly diagnosed multiple myeloma]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi. 2017;38 2:129–33. Wang PF, Li YC, Xu YX, Wang XM, Guo LF, Fu C. [Role of whole-body diffusion weighted imaging (WB-DWI) in the diagnosis and monitoring of newly diagnosed multiple myeloma]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi. 2017;38 2:129–33.
25.
Zurück zum Zitat Klein B, Tarte K, Jourdan M, Mathouk K, Moreaux J, Jourdan E, et al. Survival and proliferation factors of normal and malignant plasma cells. Int J Hematol. 2003;78:106–13.CrossRef Klein B, Tarte K, Jourdan M, Mathouk K, Moreaux J, Jourdan E, et al. Survival and proliferation factors of normal and malignant plasma cells. Int J Hematol. 2003;78:106–13.CrossRef
26.
Zurück zum Zitat Weininger M, Lauterbach B, Knop S, Pabst T, Kenn W, Hahn D, et al. Whole-body MRI of multiple myeloma: comparison of different MRI sequences in assessment of different growth patterns. Eur J Radiol. 2009;69:339–45.CrossRef Weininger M, Lauterbach B, Knop S, Pabst T, Kenn W, Hahn D, et al. Whole-body MRI of multiple myeloma: comparison of different MRI sequences in assessment of different growth patterns. Eur J Radiol. 2009;69:339–45.CrossRef
27.
Zurück zum Zitat Park HY, Kim KW, Yoon MA, Lee MH, Chae EJ, Lee JH, et al. Role of whole-body MRI for treatment response assessment in multiple myeloma: comparison between clinical response and imaging response. Cancer Imaging. 2020;20:14.CrossRef Park HY, Kim KW, Yoon MA, Lee MH, Chae EJ, Lee JH, et al. Role of whole-body MRI for treatment response assessment in multiple myeloma: comparison between clinical response and imaging response. Cancer Imaging. 2020;20:14.CrossRef
28.
Zurück zum Zitat Takasu M, Kondo S, Akiyama Y, Takahashi Y, Maeda S, Baba Y, et al. Assessment of early treatment response on MRI in multiple myeloma: comparative study of whole-body diffusion-weighted and lumbar spinal MRI. PLoS ONE. 2020;15: e0229607.CrossRef Takasu M, Kondo S, Akiyama Y, Takahashi Y, Maeda S, Baba Y, et al. Assessment of early treatment response on MRI in multiple myeloma: comparative study of whole-body diffusion-weighted and lumbar spinal MRI. PLoS ONE. 2020;15: e0229607.CrossRef
29.
Zurück zum Zitat Pawlyn C, Fowkes L, Otero S, Jones JR, Boyd KD, Davies FE, et al. Whole-body diffusion-weighted MRI: a new gold standard for assessing disease burden in patients with multiple myeloma? Leukemia. 2016;30:1446–8.CrossRef Pawlyn C, Fowkes L, Otero S, Jones JR, Boyd KD, Davies FE, et al. Whole-body diffusion-weighted MRI: a new gold standard for assessing disease burden in patients with multiple myeloma? Leukemia. 2016;30:1446–8.CrossRef
30.
Zurück zum Zitat Decaux O, et al. Evaluation of whole-body diffusion-weighted magnetic resonance imaging for diagnosis and monitoring of multiple myeloma, Haematologica. 2011;96:S65–6. Decaux O, et al. Evaluation of whole-body diffusion-weighted magnetic resonance imaging for diagnosis and monitoring of multiple myeloma, Haematologica. 2011;96:S65–6.
31.
Zurück zum Zitat Brilleta É, Decauxc O, Bernardc A-M, Devillersc A, Chapellec T, Bertaud V, et al. Comparison between whole-body diffusion MRI and 18FDG PET/CT in the diagnosis of symptomatic myeloma. Medecine Nucleaire. 2012;36:313–9. Brilleta É, Decauxc O, Bernardc A-M, Devillersc A, Chapellec T, Bertaud V, et al. Comparison between whole-body diffusion MRI and 18FDG PET/CT in the diagnosis of symptomatic myeloma. Medecine Nucleaire. 2012;36:313–9.
32.
Zurück zum Zitat Giles SL, deSouza NM, Collins DJ, Morgan VA, West S, Davies FE, et al. Assessing myeloma bone disease with whole-body diffusion-weighted imaging: comparison with x-ray skeletal survey by region and relationship with laboratory estimates of disease burden. Clin Radiol. 2015;70:614–21.CrossRef Giles SL, deSouza NM, Collins DJ, Morgan VA, West S, Davies FE, et al. Assessing myeloma bone disease with whole-body diffusion-weighted imaging: comparison with x-ray skeletal survey by region and relationship with laboratory estimates of disease burden. Clin Radiol. 2015;70:614–21.CrossRef
33.
Zurück zum Zitat Barwick T, Orton M, Koh DM, Kaiser M, Rockall A, Tunariu N, et al. Repeatability and reproducibility of apparent diffusion coefficient and fat fraction measurement of focal myeloma lesions on whole body magnetic resonance imaging. BJR The British Institute of Radiology. 2021;94:20200682.CrossRef Barwick T, Orton M, Koh DM, Kaiser M, Rockall A, Tunariu N, et al. Repeatability and reproducibility of apparent diffusion coefficient and fat fraction measurement of focal myeloma lesions on whole body magnetic resonance imaging. BJR The British Institute of Radiology. 2021;94:20200682.CrossRef
34.
Zurück zum Zitat Mosebach J, Sachpekidis C, Fard N, Wilhelm T, Wilhelm M, Hillengass J, et al. Characterization of multiple myeloma osseous lesions and diffuse infiltration pattern by 18F-FDG-PET/CT, static MRI and diffusion-weighted MR Imaging (DWI-MRI): a comparative multimodality imaging study. Cancer Imaging. 2014;14:P33–P33.CrossRef Mosebach J, Sachpekidis C, Fard N, Wilhelm T, Wilhelm M, Hillengass J, et al. Characterization of multiple myeloma osseous lesions and diffuse infiltration pattern by 18F-FDG-PET/CT, static MRI and diffusion-weighted MR Imaging (DWI-MRI): a comparative multimodality imaging study. Cancer Imaging. 2014;14:P33–P33.CrossRef
35.
Zurück zum Zitat Berno T, et al. Whole-body diffusion-weighted MRI and 18F-FDG PET-CT in the assessment of bone disease in multiple myeloma. Clinical Lymphoma, Myeloma and Leukemia. 2013;13:S84. Berno T, et al. Whole-body diffusion-weighted MRI and 18F-FDG PET-CT in the assessment of bone disease in multiple myeloma. Clinical Lymphoma, Myeloma and Leukemia. 2013;13:S84.
36.
Zurück zum Zitat Rasche L, Angtuaco E, McDonald JE, Buros A, Stein C, Pawlyn C, et al. Low expression of hexokinase-2 is associated with false-negative FDG–positron emission tomography in multiple myeloma. Blood. 2017;130:30–4.CrossRef Rasche L, Angtuaco E, McDonald JE, Buros A, Stein C, Pawlyn C, et al. Low expression of hexokinase-2 is associated with false-negative FDG–positron emission tomography in multiple myeloma. Blood. 2017;130:30–4.CrossRef
37.
Zurück zum Zitat Chenevert TL, Sundgren PC, Ross BD. Diffusion imaging: insight to cell status and cytoarchitecture. Neuroimaging Clinics Elsevier. 2006;16:619–32.CrossRef Chenevert TL, Sundgren PC, Ross BD. Diffusion imaging: insight to cell status and cytoarchitecture. Neuroimaging Clinics Elsevier. 2006;16:619–32.CrossRef
38.
Zurück zum Zitat Hillengass J, Bäuerle T, Bartl R, Andrulis M, McClanahan F, Laun FB, et al. Diffusion-weighted imaging for non-invasive and quantitative monitoring of bone marrow infiltration in patients with monoclonal plasma cell disease: a comparative study with histology. Br J Haematol. 2011;153:721–8.CrossRef Hillengass J, Bäuerle T, Bartl R, Andrulis M, McClanahan F, Laun FB, et al. Diffusion-weighted imaging for non-invasive and quantitative monitoring of bone marrow infiltration in patients with monoclonal plasma cell disease: a comparative study with histology. Br J Haematol. 2011;153:721–8.CrossRef
39.
Zurück zum Zitat Lemke A, et al. Differentiation of pancreas carcinoma from healthy pancreatic tissue using multiple b-values: comparison of apparent diffusion coefficient and intravoxel incoherent motion derived parameters. Invest Radiol. 2009;44(12):769–75. (https://pubmed.ncbi.nlm.nih.gov/19838121/) Lemke A, et al. Differentiation of pancreas carcinoma from healthy pancreatic tissue using multiple b-values: comparison of apparent diffusion coefficient and intravoxel incoherent motion derived parameters. Invest Radiol. 2009;44(12):769–75. (https://​pubmed.​ncbi.​nlm.​nih.​gov/​19838121/​)
40.
Zurück zum Zitat Luciani A, Vignaud A, Cavet M, Nhieu JTV, Mallat A, Ruel L, et al. Liver cirrhosis: intravoxel incoherent motion MR imaging – pilot study. Radiology. 2008;249:891–9.CrossRef Luciani A, Vignaud A, Cavet M, Nhieu JTV, Mallat A, Ruel L, et al. Liver cirrhosis: intravoxel incoherent motion MR imaging – pilot study. Radiology. 2008;249:891–9.CrossRef
41.
Zurück zum Zitat Le Bihan D. Intravoxel incoherent motion imaging using steady-state free precession. Magn Reson Med. 1988;7:346–51 (John Wiley & Sons, Ltd).CrossRef Le Bihan D. Intravoxel incoherent motion imaging using steady-state free precession. Magn Reson Med. 1988;7:346–51 (John Wiley & Sons, Ltd).CrossRef
42.
Zurück zum Zitat Sezer O, Niemöller K, Jakob C, Zavrski I, Heider U, Eucker J, et al. Relationship between bone marrow angiogenesis and plasma cell infiltration and serum beta2-microglobulin levels in patients with multiple myeloma. Annals of hematology. 2001;80(10):598–601. CrossRef Sezer O, Niemöller K, Jakob C, Zavrski I, Heider U, Eucker J, et al. Relationship between bone marrow angiogenesis and plasma cell infiltration and serum beta2-microglobulin levels in patients with multiple myeloma. Annals of hematology. 2001;80(10):598–601. CrossRef
43.
Zurück zum Zitat Winfield JM, Poillucci G, Blackledge MD, Collins DJ, Shah V, Tunariu N, et al. Apparent diffusion coefficient of vertebral haemangiomas allows differentiation from malignant focal deposits in whole-body diffusion-weighted MRI. Eur Radiol. 2018;28:1687–91.CrossRef Winfield JM, Poillucci G, Blackledge MD, Collins DJ, Shah V, Tunariu N, et al. Apparent diffusion coefficient of vertebral haemangiomas allows differentiation from malignant focal deposits in whole-body diffusion-weighted MRI. Eur Radiol. 2018;28:1687–91.CrossRef
44.
Zurück zum Zitat Messiou C, Giles S, Collins DJ, West S, Davies FE, Morgan GJ, et al. Assessing response of myeloma bone disease with diffusion-weighted MRI. Br J Radiol. 2012;85:e1198–203.CrossRef Messiou C, Giles S, Collins DJ, West S, Davies FE, Morgan GJ, et al. Assessing response of myeloma bone disease with diffusion-weighted MRI. Br J Radiol. 2012;85:e1198–203.CrossRef
45.
Zurück zum Zitat Lavdas I, Rockall AG, Castelli F, Sandhu RS, Papadaki A, Honeyfield L, et al. Apparent diffusion coefficient of normal abdominal organs and bone marrow from whole-body DWI at 1.5 T: the effect of sex and age. Am J Roentgenol Am Roentgen Ray Soc. 2015;205:242–50.CrossRef Lavdas I, Rockall AG, Castelli F, Sandhu RS, Papadaki A, Honeyfield L, et al. Apparent diffusion coefficient of normal abdominal organs and bone marrow from whole-body DWI at 1.5 T: the effect of sex and age. Am J Roentgenol Am Roentgen Ray Soc. 2015;205:242–50.CrossRef
46.
Zurück zum Zitat Herneth AM, Friedrich K, Weidekamm C, Schibany N, Krestan C, Czerny C, et al. Diffusion weighted imaging of bone marrow pathologies. Eur J Radiol. 2005;55:74–83.CrossRef Herneth AM, Friedrich K, Weidekamm C, Schibany N, Krestan C, Czerny C, et al. Diffusion weighted imaging of bone marrow pathologies. Eur J Radiol. 2005;55:74–83.CrossRef
47.
Zurück zum Zitat Dutoit JC, Vanderkerken MA, Anthonissen J, Dochy F, Verstraete KL. The diagnostic value of SE MRI and DWI of the spine in patients with monoclonal gammopathy of undetermined significance, smouldering myeloma and multiple myeloma. Eur Radiol. 2014;24:2754–65.CrossRef Dutoit JC, Vanderkerken MA, Anthonissen J, Dochy F, Verstraete KL. The diagnostic value of SE MRI and DWI of the spine in patients with monoclonal gammopathy of undetermined significance, smouldering myeloma and multiple myeloma. Eur Radiol. 2014;24:2754–65.CrossRef
48.
Zurück zum Zitat Messiou C, Collins DJ, Morgan VA, Desouza NM. Optimising diffusion weighted MRI for imaging metastatic and myeloma bone disease and assessing reproducibility. Eur Radiol. 2011;21:1713–8.CrossRef Messiou C, Collins DJ, Morgan VA, Desouza NM. Optimising diffusion weighted MRI for imaging metastatic and myeloma bone disease and assessing reproducibility. Eur Radiol. 2011;21:1713–8.CrossRef
49.
Zurück zum Zitat Hernandez JM, Montesinos O, Mateo AG, Queizán JA, del Peral GS, Olivier C, et al. Usefulness of whole-body diffusion-weighted MRI (WB-MRI) with apparent diffusion coefficient (ADC) in the differentiation of monoclonal gammopathies. Clin Lymphoma, Myeloma and Leukemia. 2015;15:e90-1 (Elsevier).CrossRef Hernandez JM, Montesinos O, Mateo AG, Queizán JA, del Peral GS, Olivier C, et al. Usefulness of whole-body diffusion-weighted MRI (WB-MRI) with apparent diffusion coefficient (ADC) in the differentiation of monoclonal gammopathies. Clin Lymphoma, Myeloma and Leukemia. 2015;15:e90-1 (Elsevier).CrossRef
50.
Zurück zum Zitat Burns R, et al. Whole-body PET/MRI for multiple myeloma staging: Impact of 18F-FDG uptake and MR sequence design on focal lesion and bone marrow infiltration assessment. Eur J Nucl Med Mol Imaging. 2018;45:S235. Burns R, et al. Whole-body PET/MRI for multiple myeloma staging: Impact of 18F-FDG uptake and MR sequence design on focal lesion and bone marrow infiltration assessment. Eur J Nucl Med Mol Imaging. 2018;45:S235. 
51.
Zurück zum Zitat Squillaci E, Bolacchi F, Altobelli S, Franceschini L, Bergamini A, Cantonetti M, et al. Pre-treatment staging of multiple myeloma patients: comparison of whole-body diffusion weighted imaging with whole-body T1-weighted contrast-enhanced imaging. Acta Radiol SAGE Publications. 2015;56:733–8.CrossRef Squillaci E, Bolacchi F, Altobelli S, Franceschini L, Bergamini A, Cantonetti M, et al. Pre-treatment staging of multiple myeloma patients: comparison of whole-body diffusion weighted imaging with whole-body T1-weighted contrast-enhanced imaging. Acta Radiol SAGE Publications. 2015;56:733–8.CrossRef
52.
Zurück zum Zitat Auger S, Exbrayat C, Decoux E, Aufort S, Plassot C, Donadio D, et al. Contribution of diffusion and ADC sequences in whole body MRI for myeloma staging. Haematologica. Ferrata Storti Foundation via Guiseppe Belli 4, 27100 Pavia, Italy; 2013. p. 599–599. Auger S, Exbrayat C, Decoux E, Aufort S, Plassot C, Donadio D, et al. Contribution of diffusion and ADC sequences in whole body MRI for myeloma staging. Haematologica. Ferrata Storti Foundation via Guiseppe Belli 4, 27100 Pavia, Italy; 2013. p. 599–599.
53.
Zurück zum Zitat Bourillon C, Rahmouni A, Lin C, Belhadj K, Beaussart P, Vignaud A, et al. Intravoxel incoherent motion diffusion-weighted imaging of multiple myeloma lesions: correlation with whole-body dynamic contrast agent–enhanced MR imaging. Radiol Radiol Soc North Am. 2015;277:773–83. Bourillon C, Rahmouni A, Lin C, Belhadj K, Beaussart P, Vignaud A, et al. Intravoxel incoherent motion diffusion-weighted imaging of multiple myeloma lesions: correlation with whole-body dynamic contrast agent–enhanced MR imaging. Radiol Radiol Soc North Am. 2015;277:773–83.
54.
Zurück zum Zitat Shah R, Stieltjes B, Andrulis M, Pfeiffer R, Sumkauskaite M, Delorme S, et al. Intravoxel incoherent motion imaging for assessment of bone marrow infiltration of monoclonal plasma cell diseases. Ann Hematol. 2013;92:1553–7 (Springer).CrossRef Shah R, Stieltjes B, Andrulis M, Pfeiffer R, Sumkauskaite M, Delorme S, et al. Intravoxel incoherent motion imaging for assessment of bone marrow infiltration of monoclonal plasma cell diseases. Ann Hematol. 2013;92:1553–7 (Springer).CrossRef
55.
Zurück zum Zitat Padhani A. Guidelines for acquisition, interpretation, and reporting of whole-body MRI in myeloma: myeloma response assessment and diagnosis system. Radiology. 2019;291:5–13.CrossRef Padhani A. Guidelines for acquisition, interpretation, and reporting of whole-body MRI in myeloma: myeloma response assessment and diagnosis system. Radiology. 2019;291:5–13.CrossRef
56.
Zurück zum Zitat Sommer G, Klarhöfer M, Lenz C, Scheffler K, Bongartz G, Winter L. Signal characteristics of focal bone marrow lesions in patients with multiple myeloma using whole body T1w-TSE, T2w-STIR and diffusion-weighted imaging with background suppression. Eur Radiol. 2011;21:857–62 (Springer).CrossRef Sommer G, Klarhöfer M, Lenz C, Scheffler K, Bongartz G, Winter L. Signal characteristics of focal bone marrow lesions in patients with multiple myeloma using whole body T1w-TSE, T2w-STIR and diffusion-weighted imaging with background suppression. Eur Radiol. 2011;21:857–62 (Springer).CrossRef
57.
Zurück zum Zitat Wu C, Huang J, Xu W-B, Guan Y-J, Ling H-W, Mi J-Q, et al. Discriminating depth of response to therapy in multiple myeloma using whole-body diffusion-weighted MRI with apparent diffusion coefficient: preliminary results from a single-center study. Acad Radiol. 2018;25:904–14 (Elsevier).CrossRef Wu C, Huang J, Xu W-B, Guan Y-J, Ling H-W, Mi J-Q, et al. Discriminating depth of response to therapy in multiple myeloma using whole-body diffusion-weighted MRI with apparent diffusion coefficient: preliminary results from a single-center study. Acad Radiol. 2018;25:904–14 (Elsevier).CrossRef
58.
Zurück zum Zitat Huang W, Yang M, Sui W, Deng S, Liu W, Ji X, et al. The correlation between findings of whole-body diffusion weighted imaging and clinical result in patients with multiple myeloma. Zhonghua Yi Xue Za Zhi. 2019;99:664–8. Huang W, Yang M, Sui W, Deng S, Liu W, Ji X, et al. The correlation between findings of whole-body diffusion weighted imaging and clinical result in patients with multiple myeloma. Zhonghua Yi Xue Za Zhi. 2019;99:664–8.
59.
Zurück zum Zitat Lacognata C, Crimì F, Guolo A, Varin C, De March E, Vio S, et al. Diffusion-weighted whole-body MRI for evaluation of early response in multiple myeloma. Clin Radiol. 2017;72:850–7 (Elsevier).CrossRef Lacognata C, Crimì F, Guolo A, Varin C, De March E, Vio S, et al. Diffusion-weighted whole-body MRI for evaluation of early response in multiple myeloma. Clin Radiol. 2017;72:850–7 (Elsevier).CrossRef
60.
Zurück zum Zitat Horger M, Weisel K, Bares R, Ernemann U, Claussen C, Lichy M, et al. Modern imaging techniques during therapy in patients with multiple myeloma. Acta radiologica. SAGE Publications Sage UK: London, England; 2011;52:881–8. Horger M, Weisel K, Bares R, Ernemann U, Claussen C, Lichy M, et al. Modern imaging techniques during therapy in patients with multiple myeloma. Acta radiologica. SAGE Publications Sage UK: London, England; 2011;52:881–8.
61.
Zurück zum Zitat Bonaffini PA, Ippolito D, Casiraghi A, Besostri V, Franzesi CT, Sironi S. Apparent diffusion coefficient maps integrated in whole-body MRI examination for the evaluation of tumor response to chemotherapy in patients with multiple myeloma. Acad Radiol. 2015;22:1163–71 (Elsevier).CrossRef Bonaffini PA, Ippolito D, Casiraghi A, Besostri V, Franzesi CT, Sironi S. Apparent diffusion coefficient maps integrated in whole-body MRI examination for the evaluation of tumor response to chemotherapy in patients with multiple myeloma. Acad Radiol. 2015;22:1163–71 (Elsevier).CrossRef
62.
Zurück zum Zitat Wang M, Delasalle K, Feng L, Thomas S, Giralt S, Qazilbash M, et al. CR represents an early index of potential long survival in multiple myeloma. Bone Marrow Transplant. 2010;45:498–504 (Nature Publishing Group).CrossRef Wang M, Delasalle K, Feng L, Thomas S, Giralt S, Qazilbash M, et al. CR represents an early index of potential long survival in multiple myeloma. Bone Marrow Transplant. 2010;45:498–504 (Nature Publishing Group).CrossRef
63.
Zurück zum Zitat Moreau P, Attal M, Facon T. Frontline therapy of multiple myeloma. Blood. 2015;125:3076–84.CrossRef Moreau P, Attal M, Facon T. Frontline therapy of multiple myeloma. Blood. 2015;125:3076–84.CrossRef
64.
Zurück zum Zitat Rosiñol L, Oriol A, Teruel AI, Hernández D, López-Jiménez J, de la Rubia J, et al. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood, The Journal of the American Society of Hematology. American Society of Hematology Washington, DC; 2012;120:1589–96. Rosiñol L, Oriol A, Teruel AI, Hernández D, López-Jiménez J, de la Rubia J, et al. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood, The Journal of the American Society of Hematology. American Society of Hematology Washington, DC; 2012;120:1589–96.
65.
Zurück zum Zitat Rasche L, Schinke CD, Alapat D, Gershner G, Johnson SK, Thanendrarajan S, et al. Functional imaging detects residual disease in MRD-negative multiple myeloma patients who subsequently relapse. Blood. 2017;130:4510 (Elsevier). Rasche L, Schinke CD, Alapat D, Gershner G, Johnson SK, Thanendrarajan S, et al. Functional imaging detects residual disease in MRD-negative multiple myeloma patients who subsequently relapse. Blood. 2017;130:4510 (Elsevier).
66.
Zurück zum Zitat Zamagni E, Tacchetti P, Terragna C, Cavo M. Multiple myeloma: disease response assessment. Expert Rev Hematol. 2016;9:831–7 (Taylor & Francis).CrossRef Zamagni E, Tacchetti P, Terragna C, Cavo M. Multiple myeloma: disease response assessment. Expert Rev Hematol. 2016;9:831–7 (Taylor & Francis).CrossRef
67.
Zurück zum Zitat Stetler-Stevenson M, Paiva B, Stoolman L, Lin P, Jorgensen JL, Orfao A, et al. Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition. Cytometry Part B Clin Cytometry. 2016;90:26–30 (Wiley Online Library).CrossRef Stetler-Stevenson M, Paiva B, Stoolman L, Lin P, Jorgensen JL, Orfao A, et al. Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition. Cytometry Part B Clin Cytometry. 2016;90:26–30 (Wiley Online Library).CrossRef
68.
Zurück zum Zitat Spina F, Potepan P, Trecate G, Montin E, Montefusco V, Laffranchi A, et al. Results of a prospective study comparing whole-body diffusion-weighted magnetic resonance imaging with skeletal X-ray and magnetic resonance of the spine for assessing bone disease in multiple myeloma. Blood. 2012;120:2913 (Elsevier).CrossRef Spina F, Potepan P, Trecate G, Montin E, Montefusco V, Laffranchi A, et al. Results of a prospective study comparing whole-body diffusion-weighted magnetic resonance imaging with skeletal X-ray and magnetic resonance of the spine for assessing bone disease in multiple myeloma. Blood. 2012;120:2913 (Elsevier).CrossRef
69.
Zurück zum Zitat Fernández-Poveda E, Cabañas V, Moreno MJ, Blanquer Blanquer M, Moraleda JM. Prognostic value of diffusion-weighted magnetic resonance imaging in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood. 2019;134:3146.CrossRef Fernández-Poveda E, Cabañas V, Moreno MJ, Blanquer Blanquer M, Moraleda JM. Prognostic value of diffusion-weighted magnetic resonance imaging in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood. 2019;134:3146.CrossRef
70.
Zurück zum Zitat Latifoltojar A, Hall-Craggs M, Rabin N, Popat R, Bainbridge A, Dikaios N, et al. Whole body magnetic resonance imaging in newly diagnosed multiple myeloma: early changes in lesional signal fat fraction predict disease response. Br J Haematol. 2017;176:222–33 (Wiley Online Library).CrossRef Latifoltojar A, Hall-Craggs M, Rabin N, Popat R, Bainbridge A, Dikaios N, et al. Whole body magnetic resonance imaging in newly diagnosed multiple myeloma: early changes in lesional signal fat fraction predict disease response. Br J Haematol. 2017;176:222–33 (Wiley Online Library).CrossRef
71.
Zurück zum Zitat Padhani AR, Koh D-M, Collins DJ. Whole-body diffusion-weighted MR imaging in cancer: current status and research directions. Radiology. 2011;261:700–18 (Radiological Society of North America, Inc.).CrossRef Padhani AR, Koh D-M, Collins DJ. Whole-body diffusion-weighted MR imaging in cancer: current status and research directions. Radiology. 2011;261:700–18 (Radiological Society of North America, Inc.).CrossRef
73.
Zurück zum Zitat Lecouvet FE, Vekemans M-C, Van Den Berghe T, Verstraete K, Kirchgesner T, Acid S, et al. Imaging of treatment response and minimal residual disease in multiple myeloma: state of the art WB-MRI and PET/CT. Skelet Radiol. Springer; 2021;1–22. ( https://pubmed.ncbi.nlm.nih.gov/34363522/) Lecouvet FE, Vekemans M-C, Van Den Berghe T, Verstraete K, Kirchgesner T, Acid S, et al. Imaging of treatment response and minimal residual disease in multiple myeloma: state of the art WB-MRI and PET/CT. Skelet Radiol. Springer; 2021;1–22. ( https://​pubmed.​ncbi.​nlm.​nih.​gov/​34363522/​
74.
Zurück zum Zitat Mahale A, Maruvaneni S, Kumar A, Ullal S, Fernandes M. Role of Diffusion Weighted imaging in differentiating benign from pathological vertebral collapse using ADC values. J Clin Diagn Res 2019;13. Mahale A, Maruvaneni S, Kumar A, Ullal S, Fernandes M. Role of Diffusion Weighted imaging in differentiating benign from pathological vertebral collapse using ADC values. J Clin Diagn Res 2019;13.
Metadaten
Titel
Diffusion-weighted imaging (DWI) in diagnosis, staging, and treatment response assessment of multiple myeloma: a systematic review and meta-analysis
verfasst von
Pooya Torkian
Bahar Mansoori
Jens Hillengass
Javid Azadbakht
Sina Rashedi
Sarah S. Lee
Behrang Amini
Pietro Andrea Bonaffini
Majid Chalian
Publikationsdatum
26.07.2022
Verlag
Springer Berlin Heidelberg
Erschienen in
Skeletal Radiology / Ausgabe 3/2023
Print ISSN: 0364-2348
Elektronische ISSN: 1432-2161
DOI
https://doi.org/10.1007/s00256-022-04119-0

Weitere Artikel der Ausgabe 3/2023

Skeletal Radiology 3/2023 Zur Ausgabe

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

S3-Leitlinie zu Pankreaskrebs aktualisiert

23.04.2024 Pankreaskarzinom Nachrichten

Die Empfehlungen zur Therapie des Pankreaskarzinoms wurden um zwei Off-Label-Anwendungen erweitert. Und auch im Bereich der Früherkennung gibt es Aktualisierungen.

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

18.04.2024 Pädiatrische Notfallmedizin Nachrichten

Im Choosing-Wisely-Programm, das für die deutsche Initiative „Klug entscheiden“ Pate gestanden hat, sind erstmals Empfehlungen zum Umgang mit Notfällen von Kindern erschienen. Fünf Dinge gilt es demnach zu vermeiden.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.